Announced submission and validation of Marketing Authorization Application (MAA) submission to the European Medicines Agency (EMA) seeking marketing approval of DCCR (marketed in the U.S. as VYKAT XR) ...

New approach finds ‘parent-of-origin’ effects in more than a dozen genes — without the need for parental data.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025.

Discover key insights from Soleno Therapeutics' Q2 2025 earnings call, highlighting Vykat XR's strong launch, revenue growth, EU expansion efforts & ...